Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Iron Deficiency Anaemia Treatment Market Size, Share, Demand, Research: By Drug Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumarate, Ferric Hydroxide, Sodium Ferric Gluconate, Iron Carbohydrates, Others; By Therapy: Oral Iron Therapy, Others; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Iron Deficiency Anaemia Treatment Market Outlook
The growth of the global iron deficiency anaemia treatment market is driven by the rising prevalence of iron deficiency anaemia, which was close to 1.8 billion in 2021. The prevalence of iron deficiency anaemia is likely to grow at a CAGR of 4% in the forecast period of 2023-2031, which would add further growth to the treatment market.
Key Company News
In June 2021, a generic version of Feraheme was launched by Sandoz to treat patients with iron deficiency anaemia with Ferumoxytol, a high-dose intravenous iron supplement. The generic version of ferrahem (ferumoxytol injection), produced by AMAG Pharmaceuticals was approved to treat IDA in adults suffering from oral iron intolerance or chronic kidney disease, who do not respond well to oral iron.
In January 2020, the U.S. Food and Drug Administration (FDA) approved ferric derisomaltose injection, manufactured by PHARMACOSMOS A/S, for treating chronic kidney disease patients who cannot tolerate or are irresponsive to oral iron, or who are not dependent on haemodialysis for treating iron deficiency anaemia.
Introduction
A condition called anaemia occurs when the red blood cells (RBCs) or the haemoglobin concentration is insufficient. The body's tissues need haemoglobin to carry oxygen, and when a person has too few red blood cells, is malformed, or has no haemoglobin, then blood is unable to carry oxygen.
The main symptom of anaemia is a low number of red blood cells, which can cause paleness, fatigue, and weakness. The subtypes are classified according to the chronicity, size, and aetiology of the RBCs.
The loss of blood and decrease in red blood cell production can lead to anaemia due to an iron deficiency or an increase in red blood cell destruction by haemolysis. The main cause of anaemia is iron deficiency.
Iron levels can be used to categorize IDAs into mild, moderate, and severe categories. Symptoms and signs of mild to moderate disease are usually absent. Symptoms related to the severe form include fatigue, shortness of breath, or chest pain.
IDA (iron deficiency anaemia) is characterized by iron deficiency. This may be mainly due to low iron intake. IDA can also be caused by blood loss, an inability to absorb iron, and other health issues.
IDA is usually diagnosed by a physical exam and blood tests. In order to determine if the body has enough normal blood cells, iron and ferritin, a complete blood count is appropriate.
Treatment begins once IDA is diagnosed. Patients' characteristics and disease severity determine the treatment procedure. Increased consumption of iron supplements is the most common and the first prescribed treatment by doctors.
The supplements can be taken orally (Auryxia, Accrufer, and OTC) or intravenously (Venofer, Feraheme, and Monofer, among others). A blood transfusion or surgery may be needed in extreme/serious cases.
According to the global iron deficiency anaemia treatment market research report, the market can be categorised into the following segments:
Market Breakup by Drug Type
- Ferrous Sulphate
- Ferrous Gluconate
- Ferrous Fumarate
- Ferric Hydroxide
- Sodium Ferric Gluconate
- Iron Carbohydrates
- Others
Market Breakup by Route of Administration
- Tablets
- Capsules
- Liquids
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Increasing Prevalence, Rising Investment for Healthcare Infrastructure, Increasing Research and Development Activities to be the Key Market Trends
The growth of the iron deficiency anaemia treatment market is primarily driven by the rising prevalence of the disease as well as chronic kidney diseases. The market is also propelled by other factors such as the rapidly developing healthcare infrastructure.
The growth of the market can also be attributed to the rising awareness about the disease as well as its treatment by the public and private organisations.
Rising disposable incomes of the populations and the increased risk of blood dilution will also increase the demand for iron deficiency anaemia treatments. As the population ages and people lead sedentary lifestyles, the market is expected to grow further in the coming years.
The market is also witnessing rapid growth due to the increasing research and development activities. As a result, the market is expected to grow significantly over the next few years.
In addition, the approval and launch of more drugs is expected to accelerate the market growth. Rising investment in advanced technology and growth in emerging markets will act as lucrative opportunities for the growth of the iron deficiency anaemia treatment market in the coming years.
Factors like High Costs of the Treatment and Lack of Professionals are Restricting the Growth of the Market
The high cost of the treatment will hamper the growth of the market as most of the patients are unable to afford it. In the developing countries, iron deficiency anaemia treatment market will be challenged by a lack of skilled professionals and medical infrastructure.
North America Dominates the Global Iron Deficiency Anaemia Treatment Market
North America dominates the iron deficiency anaemia treatment market due to the region's well-established healthcare infrastructure. The key players will be increasingly interested in new technologies, which will add further growth to the market.
It is expected that the Asia Pacific region will also witness significant growth over the forecast period due to population growth and rise in healthcare spending.
Therapeutic Landscape
It is common for IDA patients to be prescribed oral iron supplements in pill, tablet, or syrup form in the early stages. There are several over the counter (OTC) iron remedies available in the market. The gastrointestinal side effects of oral iron reduce patient compliance. It is recommended to use intravenous iron if the patient no longer responds to these drugs or if the drugs are not working as effectively as before.
IDA Approved Drugs
Auryxia (Riona/ KRX-0502/Ferric Citrate): Akebia Therapeutics
Due to its unique chemical properties and mechanism of action, Auryxia is a calcium-free iron-based compound that doubles as a treatment for CKD patients. This drug contains a small molecule called ferric citrate as its active ingredient.
Immediately following its approval by the US Food and Drug Administration (FDA) in September 2014, the drug was marketed in the United States as a phosphate binder for hyperphosphatemia. It was approved by the FDA in 2017 for IDA, a second indication for treatment of adult patients.
Feraccru/Accrufer (Ferric Maltol/ ST10): Shield Therapeutics
Feraccru/Accrufer provides an alternative to intravenous iron therapy for patients who are intolerant to oral iron supplements.
Feraheme/Rienso (Ferumoxytol): AMAG Pharmaceuticals
For intravenous use, Feraheme contains ferumoxytol as a replacement for iron. It is an inorganic magnetite (superparamagnetic iron oxide) coated with polyglucose sorbitol carboxymethyl ether.
Clinical Trials
IDA Emerging Drugs
MPB-1514 (IOP Injection): MegaPro Biomedical
MegaPro Biomedical is developing MPB-1514/IOP injection for the treatment of IDA that is sugar-free. It is extremely safe as it follows doctor's prescription. The PEG coating would allow high-dose administration and lead to an increase in red blood cells without frequent injections. Currently, the drug is the only sugar-free injection in development.
IDAX (IHAT-02): Nemysis
Nemysis (IHAT-02/IDAX) is the first ferritin-mimic product that uses a tartrate salt to insulate the ferrihydrite nanocore of adipate-buffered ferritin. IHAT is well absorbed and maintains healthy gut bacteria. IHAT has been shown to be efficiently absorbed by humans and correct markers of iron deficiency without causing gastrointestinal side effects. As a result of this product, iron can be absorbed in the intestine in a manner similar to what happens naturally.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global iron deficiency anaemia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Amgen Inc.
- Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc
- Janssen Pharmaceuticals, Inc.
- AMAG Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Therapy |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Iron Deficiency Anaemia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Iron Deficiency Anaemia Treatment Market
8.1 Global Iron Deficiency Anaemia Treatment Market Overview
8.2 Global Iron Deficiency Anaemia Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Iron Deficiency Anaemia Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Iron Deficiency Anaemia Treatment Market Forecast Value (2023-2031)
8.3 Global Iron Deficiency Anaemia Treatment Market by Drug Type
8.3.1 Market Overview
8.3.1.1 Ferrous Sulphate
8.3.1.2 Ferrous Gluconate
8.3.1.3 Ferrous Fumarate
8.3.1.4 Ferric Hydroxide
8.3.1.5 Sodium Ferric Gluconate
8.3.1.6 Iron Carbohydrates
8.3.1.7 Others
8.4 Global Iron Deficiency Anaemia Treatment Market by Therapy
8.4.1 Market Overview
8.4.1.1 Oral Iron Therapy
8.4.1.1.1 Capsules
8.4.1.1.2 Liquids
8.4.1.2 Parenteral Iron Therapy
8.4.1.2.1 Red Blood Cell Transfusion
8.4.1.3 Others
8.5 Global Iron Deficiency Anaemia Treatment Market by Treatment Channel
8.5.1 Market Overview
8.5.1.1 Public
8.5.1.2 Private
8.6 Global Iron Deficiency Anaemia Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 North America Iron Deficiency Anaemia Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Iron Deficiency Anaemia Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Iron Deficiency Anaemia Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Iron Deficiency Anaemia Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Iron Deficiency Anaemia Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Iron Deficiency Anaemia Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Amgen Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 F. Hoffmann-La Roche Ltd
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis A.G.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Janssen Pharmaceuticals, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 AMAG Pharmaceuticals
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Teva Pharmaceutical Industries Ltd.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Zydus Lifesciences Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Covis Group S.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Apotex
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Akebia Therapeutics, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 American Regent, Inc.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Bayer Ag
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Merck & Co.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Global Iron Deficiency Anaemia Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The prevalence of iron deficiency anaemia is likely to grow at a CAGR of 4% during the forecast period of 2023-2031, which will boost the growth of the treatment market.
The high prevalence of chronic kidney disease, increasing number of patients and presence of major players focused on development, and marketing of technologically advanced products will drive the growth during the forecast period.
North America is the dominating region in the global market owing to the rising demand for the treatment in the region.
Amgen Inc., Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Janssen Pharmaceuticals, Inc., AMAG Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. are the leading companies in the market.
The high cost of treatment will hinder the market growth. Lack of awareness of the treatment will restrain the growth of market.
The loss of blood and decrease in red blood cell production can lead to anaemia due to an iron deficiency or an increase in red blood cell destruction by haemolysis. The main cause of anaemia is iron deficiency.
MegaPro Biomedical and Nemysis are the emerging drugs which would drive the market growth.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$2499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$4999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$6499-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$7999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER